Patient characteristics according to studied alterations in the study cohort
| Patient characteristics, n (%) . | Sex (n = 181) . | Age (n = 181) . | Stage (n = 180) . | IPI (n = 178) . | Subtype . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hans algorithm (n = 152) . | RNA sequencing (n = 161) . | ||||||||||||||||
| Male . | Female . | <60 y . | >60 y . | I-II . | III-IV . | Low (0-2) . | High (3-5) . | GCB . | Non-GCB . | Other* . | GCB . | ABC . | Unclassified . | . | |||
| All | 110 (61) | 71 (39) | 80 (44) | 101 (56) | 89 (49) | 91 (51) | 105 (59) | 73 (41) | 81 (45) | 71 (39) | 29 (16) | 72 (45) | 66 (41) | 23 (14) | |||
| BCL2 IHC (n = 150) | Negative | 68 (45) | 41 (60) | 27 (40) | 39 (57) | 29 (43) | 43 (63) | 25 (37) | 46 (68) | 22 (32) | 33 (49) | 25 (37) | 10 (15) | 32 (55) | 16 (28) | 10 (17) | |
| Positive | 82 (55) | 45 (55) | 37 (45) | 31 (38) | 51 (62) | 31 (38) | 50 (62) | 40 (51) | 39 (49) | 37 (45) | 37 (45) | 8 (10) | 33 (43) | 38 (49) | 6 (8) | ||
| P | .513 | .021 | .003 | .044 | .484 | .039 | |||||||||||
| BCL2 translocation (n = 152) | No | 128 (84) | 74 (58) | 54 (42) | 59 (46) | 69 (54) | 68 (54) | 59 (47) | 75 (60) | 50 (40) | 52 (41) | 61 (48) | 15 (12) | 44 (39) | 51 (45) | 18 (16) | |
| Yes | 24 (16) | 12 (50) | 12 (50) | 11 (46) | 13 (54) | 7 (29) | 17 (71) | 12 (50) | 12 (50) | 20 (83) | 2 (8) | 2 (8) | 20 (83) | 3 (13) | 1 (4) | ||
| P | .508 | 1.000 | 0044 | .376 | <.001 | <.001 | |||||||||||
| BCL2 gain/amplification (n = 181) | No | 145 (80) | 83 (57) | 62 (43) | 66 (46) | 79 (55) | 73 (50) | 72 (50) | 87 (60) | 57 (40) | 69 (48) | 53 (37) | 23 (16) | 62 (48) | 45 (35) | 21 (16) | |
| Yes | 36 (20) | 27 (75) | 9 (25) | 14 (39) | 22 (61) | 16 (46) | 19 (54) | 18 (53) | 16 (47) | 12 (33) | 18 (50) | 6 (17) | 10 (30) | 21 (64) | 2 (6) | ||
| P | .058 | .575 | .708 | .444 | .152 | .014 | |||||||||||
| MYC IHC (n = 147) | Negative | 74 (50) | 45 (61) | 29 (39) | 42 (57) | 32 (43) | 38 (51) | 36 (49) | 42 (58) | 31 (42) | 32 (43) | 27 (37) | 15 (20) | 26 (43) | 23 (38) | 12 (20) | |
| Positive | 73 (50) | 40 (55) | 73 (45) | 27 (37) | 46 (63) | 33 (46) | 39 (54) | 41 (58) | 30 (42) | 37 (51) | 33 (45) | 3 (4) | 38 (54) | 29 (41) | 4 (6) | ||
| P | .506 | .021 | .513 | 1.000 | 1.000 | .710 | |||||||||||
| MYC translocation (n = 130) | No | 112 (86) | 66 (59) | 46 (41) | 53 (47) | 59 (53) | 54 (49) | 57 (51) | 63 (57) | 47 (43) | 47 (42) | 49 (44) | 13 (14) | 42 (42) | 42 (42) | 15 (15) | |
| Yes | 18 (14) | 9 (50) | 9 (50) | 10 (56) | 8 (44) | 9 (50) | 9 (50) | 10 (59) | 7 (41) | 15 (83) | 3 (17) | 0 (0) | 12 (67) | 4 (22) | 2 (11) | ||
| P | .608 | .614 | 1.000 | 1.000 | .009 | .100 | |||||||||||
| BCL6 translocation (n = 145) | No | 120 (83) | 73 (61) | 47 (39) | 55 (46) | 65 (54) | 58 (48) | 62 (52) | 69 (58) | 50 (42) | 63 (53) | 44 (37) | 13 (11) | 86 (52) | 38 (35) | 14 (13) | |
| Yes | 25 (17) | 11 (44) | 14 (56) | 13 (52) | 12 (48) | 13 (52) | 12 (48) | 15 (63) | 9 (38) | 8 (32) | 15 (60) | 2 (8) | 7 (32) | 10 (46) | 5 (23) | ||
| P | .181 | .661 | .827 | .821 | .040 | .189 | |||||||||||
| Double expression (n = 147) | No | 99 (67) | 59 (60) | 40 (40) | 54 (55) | 45 (46) | 56 (57) | 43 (43) | 62 (53) | 36 (37) | 49 (50) | 34 (34) | 16 (16) | 44 (52) | 28 (33) | 13 (15) | |
| Yes | 48 (33) | 26 (54) | 22 (46) | 15 (31) | 33 (69) | 15 (32) | 32 (68) | 21 (46) | 25 (54) | 20 (42) | 26 (54) | 2 (4) | 20 (43) | 24 (51) | 3 (6) | ||
| P | .595 | .009 | .008 | .050 | .100 | .125 | |||||||||||
| DA BCL (n = 140) | Negative | 128 (91) | 77 (60) | 51 (40) | 61 (48) | 67 (52) | 64 (50) | 63 (50) | 74 (59) | 52 (41) | 57 (45) | 54 (42) | 17 (13) | 50 (44) | 45 (40) | 18 (16) | |
| Positive | 12 (9) | 6 (50) | 6 (50) | 7 (58) | 5 (42) | 4 (33) | 8 (67) | 5 (46) | 6 (55) | 11 (92) | 1 (8) | 0 (0) | 9 (75) | 1 (8) | 2 (17) | ||
| P | .548 | .555 | .367 | .527 | .008 | .017 | |||||||||||
| Patient characteristics, n (%) . | Sex (n = 181) . | Age (n = 181) . | Stage (n = 180) . | IPI (n = 178) . | Subtype . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hans algorithm (n = 152) . | RNA sequencing (n = 161) . | ||||||||||||||||
| Male . | Female . | <60 y . | >60 y . | I-II . | III-IV . | Low (0-2) . | High (3-5) . | GCB . | Non-GCB . | Other* . | GCB . | ABC . | Unclassified . | . | |||
| All | 110 (61) | 71 (39) | 80 (44) | 101 (56) | 89 (49) | 91 (51) | 105 (59) | 73 (41) | 81 (45) | 71 (39) | 29 (16) | 72 (45) | 66 (41) | 23 (14) | |||
| BCL2 IHC (n = 150) | Negative | 68 (45) | 41 (60) | 27 (40) | 39 (57) | 29 (43) | 43 (63) | 25 (37) | 46 (68) | 22 (32) | 33 (49) | 25 (37) | 10 (15) | 32 (55) | 16 (28) | 10 (17) | |
| Positive | 82 (55) | 45 (55) | 37 (45) | 31 (38) | 51 (62) | 31 (38) | 50 (62) | 40 (51) | 39 (49) | 37 (45) | 37 (45) | 8 (10) | 33 (43) | 38 (49) | 6 (8) | ||
| P | .513 | .021 | .003 | .044 | .484 | .039 | |||||||||||
| BCL2 translocation (n = 152) | No | 128 (84) | 74 (58) | 54 (42) | 59 (46) | 69 (54) | 68 (54) | 59 (47) | 75 (60) | 50 (40) | 52 (41) | 61 (48) | 15 (12) | 44 (39) | 51 (45) | 18 (16) | |
| Yes | 24 (16) | 12 (50) | 12 (50) | 11 (46) | 13 (54) | 7 (29) | 17 (71) | 12 (50) | 12 (50) | 20 (83) | 2 (8) | 2 (8) | 20 (83) | 3 (13) | 1 (4) | ||
| P | .508 | 1.000 | 0044 | .376 | <.001 | <.001 | |||||||||||
| BCL2 gain/amplification (n = 181) | No | 145 (80) | 83 (57) | 62 (43) | 66 (46) | 79 (55) | 73 (50) | 72 (50) | 87 (60) | 57 (40) | 69 (48) | 53 (37) | 23 (16) | 62 (48) | 45 (35) | 21 (16) | |
| Yes | 36 (20) | 27 (75) | 9 (25) | 14 (39) | 22 (61) | 16 (46) | 19 (54) | 18 (53) | 16 (47) | 12 (33) | 18 (50) | 6 (17) | 10 (30) | 21 (64) | 2 (6) | ||
| P | .058 | .575 | .708 | .444 | .152 | .014 | |||||||||||
| MYC IHC (n = 147) | Negative | 74 (50) | 45 (61) | 29 (39) | 42 (57) | 32 (43) | 38 (51) | 36 (49) | 42 (58) | 31 (42) | 32 (43) | 27 (37) | 15 (20) | 26 (43) | 23 (38) | 12 (20) | |
| Positive | 73 (50) | 40 (55) | 73 (45) | 27 (37) | 46 (63) | 33 (46) | 39 (54) | 41 (58) | 30 (42) | 37 (51) | 33 (45) | 3 (4) | 38 (54) | 29 (41) | 4 (6) | ||
| P | .506 | .021 | .513 | 1.000 | 1.000 | .710 | |||||||||||
| MYC translocation (n = 130) | No | 112 (86) | 66 (59) | 46 (41) | 53 (47) | 59 (53) | 54 (49) | 57 (51) | 63 (57) | 47 (43) | 47 (42) | 49 (44) | 13 (14) | 42 (42) | 42 (42) | 15 (15) | |
| Yes | 18 (14) | 9 (50) | 9 (50) | 10 (56) | 8 (44) | 9 (50) | 9 (50) | 10 (59) | 7 (41) | 15 (83) | 3 (17) | 0 (0) | 12 (67) | 4 (22) | 2 (11) | ||
| P | .608 | .614 | 1.000 | 1.000 | .009 | .100 | |||||||||||
| BCL6 translocation (n = 145) | No | 120 (83) | 73 (61) | 47 (39) | 55 (46) | 65 (54) | 58 (48) | 62 (52) | 69 (58) | 50 (42) | 63 (53) | 44 (37) | 13 (11) | 86 (52) | 38 (35) | 14 (13) | |
| Yes | 25 (17) | 11 (44) | 14 (56) | 13 (52) | 12 (48) | 13 (52) | 12 (48) | 15 (63) | 9 (38) | 8 (32) | 15 (60) | 2 (8) | 7 (32) | 10 (46) | 5 (23) | ||
| P | .181 | .661 | .827 | .821 | .040 | .189 | |||||||||||
| Double expression (n = 147) | No | 99 (67) | 59 (60) | 40 (40) | 54 (55) | 45 (46) | 56 (57) | 43 (43) | 62 (53) | 36 (37) | 49 (50) | 34 (34) | 16 (16) | 44 (52) | 28 (33) | 13 (15) | |
| Yes | 48 (33) | 26 (54) | 22 (46) | 15 (31) | 33 (69) | 15 (32) | 32 (68) | 21 (46) | 25 (54) | 20 (42) | 26 (54) | 2 (4) | 20 (43) | 24 (51) | 3 (6) | ||
| P | .595 | .009 | .008 | .050 | .100 | .125 | |||||||||||
| DA BCL (n = 140) | Negative | 128 (91) | 77 (60) | 51 (40) | 61 (48) | 67 (52) | 64 (50) | 63 (50) | 74 (59) | 52 (41) | 57 (45) | 54 (42) | 17 (13) | 50 (44) | 45 (40) | 18 (16) | |
| Positive | 12 (9) | 6 (50) | 6 (50) | 7 (58) | 5 (42) | 4 (33) | 8 (67) | 5 (46) | 6 (55) | 11 (92) | 1 (8) | 0 (0) | 9 (75) | 1 (8) | 2 (17) | ||
| P | .548 | .555 | .367 | .527 | .008 | .017 | |||||||||||
P calculated with χ2 test. P for subtype comparisons counted for comparison of GCB and non-GCB/ABC.
Other includes tumors with indecisive, not available, or not applicable Hans-algorithm according to tumor histology.